Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre

Vox Sanguinis

Volumn 112, Issue 1, 2017, Pages 47-55

  Amato, M ^a   Schennach, H ^a   Astl, M ^a   Chen, C Y ^b   Lin, J S ^b   Benjamin, R J ^b   Nussbaumer, W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b CERUS CORPORATION   (United States)

Author keywords

amotosalen; haemovigilance; INTERCEPT Blood System; pathogen inactivation; platelets; safety

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE; FUROCOUMARIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; APHERESIS DEVICE; ARTICLE; BLOOD TRANSFUSION REACTION; CANCER PATIENT; CHILD; CHILL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; FEMALE; GRAFT VERSUS HOST REACTION; HEART SURGERY; HEMATOLOGY; HOSPITAL; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OBSERVATIONAL STUDY; PATHOGEN REDUCTION SYSTEM; PATIENT SAFETY; PEDIATRICS; PLASMA TRANSFUSION; PRIORITY JOURNAL; PRURITUS; PUVA; RETROSPECTIVE STUDY; SEPSIS; SURGICAL PATIENT; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; THROMBOELASTOGRAPH; TRANSFUSION RELATED ACUTE LUNG INJURY; URTICARIA; VIRUS INFECTION; ADVERSE EFFECTS; AUSTRIA; BLOOD COMPONENT THERAPY; CYTOLOGY; DRUG EFFECTS; ERYTHROCYTE TRANSFUSION; MIDDLE AGED; PRESCHOOL CHILD; RADIATION RESPONSE; THROMBOCYTE; TIME FACTOR; ULTRAVIOLET RADIATION; VERY ELDERLY; VIRUS INACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; FUROCOUMARINS; HOSPITALS; HUMANS; INFANT; MALE; MIDDLE AGED; PLATELET TRANSFUSION; TIME FACTORS; ULTRAVIOLET RAYS; VIRUS INACTIVATION; YOUNG ADULT;

EID: 85007360645     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12456     Document Type: Article

References (16)

1. Lin L, Dikeman R, Molini B, et al.: Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44:1496–1504
2. Lin L, Hanson CV, Alter HJ, et al.: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580–590
3. McCullough J, Vesole DH, Benjamin RJ, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534–1541
4. Osselaer JC, Doyen C, Defoin L, et al.: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:1412–1422
5. Cazenave JP, Isola H, Waller C, et al.: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622–629
6. Lozano M, Knutson F, Tardivel R, et al.: A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393–401
7. Benjamin RJ: Transfusion-related sepsis: a silent epidemic. Blood 2016; 127:380–381
8. van Rhenen D, Gulliksson H, Cazenave JP, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426–2433.
9. Kerkhoffs JL, van Putten WL, Novotny VM, et al.: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209–217.
10. Michelson AD, MacGregor H, Barnard MR, et al.: Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71:633–640
11. Kestin AS, Valeri CR, Khuri SF, et al.: The platelet function defect of cardiopulmonary bypass. Blood 1993; 82:107–117
12. Al-Riyami AZ, Al-Khabori M, Baskaran B, et al.: Intra-operative cell salvage in cardiac surgery may increase platelet transfusion requirements: a cohort study. Vox Sang 2015; 109:280–286
13. O'Connor SA, Amour J, Mercadier A, et al.: Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv 2015; 8:e002786
14. Knutson F, Osselaer J, Pierelli L, et al.: A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015; 109:343–352
15. Corash L, Benjamin RJ: The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 2016; 56(Suppl 1):S29–S38
16. Ruesch M, Jutzi M, Stoller R: 2 years experience with pathogen inactivation for all platelet concentrates in Switzerland. (2014). Available at https://www.swissmedic.ch/marktueberwachung [Last accessed 1 December 2015]